GlassScriptPhysician profile
Daniel Duncan Dawson
NPI 1790890259
$2,326.23
in general payments reported to CMS, 2019-2025
30 companies · $516 in 2025
The $516 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.25 · 2020: $359 · 2021: $228 · 2022: $332 · 2023: $431 · 2024: $368 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $291.62 | 2020-2025 | Evenity |
| Biogen, INC. | $240.09 | 2024-2025 | Zurzuvae |
| Intuitive Surgical, INC. | $229.73 | 2023-2025 | Da Vinci Surgical System |
| Abbvie INC. | $222.71 | 2020-2023 | Lo Loestrin Fe, Liletta, Orilissa |
| Pfizer INC. | $144.50 | 2021-2024 | |
| Exeltis, USA INC. | $135.56 | 2020-2025 | Slynd |
| Sumitomo Pharma America, INC. | $104.16 | 2025 | Gemtesa |
| Coopersurgical, INC. | $97.01 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.82 | 2020-2023 | |
| Evofem Biosciences, INC. | $80.68 | 2021-2024 | Phexxi |
| Novo Nordisk INC | $78.10 | 2021-2024 | Wegovy |
| Astellas Pharma US INC | $76.46 | 2021-2024 | Veozah |
| Organon LLC | $57.24 | 2023-2024 | Nexplanon |
| Avanos Medical | $54.97 | 2020-2023 | On-Q* Pump and Accessories |
| Allergan, INC. | $46.14 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $43.12 | 2023-2025 | |
| Lupin INC. | $39.81 | 2019-2020 | |
| Agile Therapeutics, INC. | $35.61 | 2022-2023 | Twirla |
| Shield Therapeutics INC | $34.96 | 2024 | |
| Merck Sharp & Dohme LLC | $32.96 | 2022-2023 | Gardasil 9 |
| Therapeuticsmd, INC. | $27.25 | 2022 | |
| Acessa Health INC. | $26.70 | 2020 | |
| Duchesnay USA Incorporated | $23.60 | 2019 | |
| Dexcom, INC. | $22.27 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $21.66 | 2022 | |
| Avion Pharmaceuticals | $18.95 | 2022 | |
| Radius Health, INC. | $14.74 | 2019 | |
| Minerva Surgical, INC | $13.69 | 2025 | |
| Millicent US INC | $13.44 | 2024 | Femring, Intrarosa |
| Channel Medsystems, INC. | $6.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.